Indegene (INDGN) Q2 25/26 earnings summary

Executive summary

• Q2 FY26 revenue reached INR 8,042 million, up 17.1% YoY, with strong deal wins, robust pipeline, and continued execution momentum, especially in enterprise commercial and medical segments.

• Recent acquisitions of BioPharm, Warn & Co, and MJL Communications Group Ltd enhance capabilities and growth prospects, with integration and financial consolidation underway.

• Strategic focus on renewals, new wins, technology enablement, and AI-driven client solutions, supported by investments in GenAI and digital platforms.

• Board approved unaudited financial results for Q2 and H1 FY26, with an unmodified auditor's opinion and CFO declaration.

• Allotment of shares under ESOP, RSU, and CSOP plans was approved.

Financial highlights

• Q2 FY26 consolidated revenue: INR 8,042 million (+17.1% YoY); H1 FY26 revenue: INR 15,650 million (+14.8% YoY).

• Q2 FY26 PAT: INR 1,021 million (+11.3% YoY); H1 FY26 PAT: INR 2,185 million (+21.8% YoY).

• Q2 FY26 EBITDA margin: 18.2%; PAT margin: 12.7%.

• Cash and cash equivalents as of September 30, 2025: INR 17,280 million (consolidated); $210 million (USD equivalent); standalone: INR 353 million.

• Basic EPS for Q2 FY26: ₹4.26; H1 FY26: ₹9.12.

Outlook and guidance

• Management expects near-term margin compression of 1–1.5% due to investments, with recovery to historical levels over 6–8 quarters as growth accelerates.

• No formal revenue guidance, but management is optimistic about higher growth rates, supported by a strong deal pipeline and market opportunities.

• Investment in Indegene Ireland Limited aims to expand business operations and support capex requirements, with completion targeted by December 31, 2026.